nach oben

Erschienen in:

03.02.2024 | Original Article

Myofibroblast and pro-fibrotic cytokines in fibrosis of IgG4-related disease (IgG4-RD) patients from South Asia: preliminary data

verfasst von: Josna Joseph, V. Prabhu, Meera Thomas, Reka Karuppusami, Thomas Alex Kodiatte, Rajiv Michael, Manbha L. Rymbai, John Mathew

Erschienen in: Clinical Rheumatology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Fibrosis is a typical pathological characteristic in IgG4-RD patients and often irreversible. There exists a lack of suitable markers for detection of earlier onset of fibrosis in various organs in IgG4-RD patients. Hence, this study aims at analysing ambispectively the myofibroblasts and the pro-fibrotic cytokines, IFN gamma and IL-33 involved in IgG4-RD associated fibrosis in South Asian patients.

Method

Archived biopsy samples of definite/probable/possible cases of IgG4-RD, classified according to diagnostic criteria, taken from patients who attended the OPD and IPD of our tertiary care centre during January 2015–January 2020 were chosen for this study. The paraffin sections were examined qualitatively for fibrosis and the excessive collagen deposition by Hematoxylin & Eosin and Masson’s Trichrome staining. Also, the presence of alpha-Smooth muscle actin (α-SMA) expressing myofibroblasts and the involvement of pro-fibrotic cytokines (IFN-gamma, IL-33) were assessed by Immunohistochemistry and scored semi-quantitatively (+mild, ++moderate, +++ severe). Serum IL-33 levels were analysed by indirect Elisa (R & D Systems).

Results

Myofibroblasts were present in 10/12 biopsy samples, in moderate levels in 4 (33%) and very high levels (+++) in 3 (25%) of the patients. IFN-gamma was expressed at low levels in 6 (50%) and absent in 6 (50%). All patients showed IL-33 expression with very high levels in tissue (6, 50%), as well as in serum samples.

Conclusion

The findings of this study reinforce the role of myofibroblasts and profibrotic cytokines like IL-33 in fibrosis of Ig4-RD patients, pointing to their potential as earlier predictive markers of onset and extent of fibrosis.

Brito-Zerón P, Ramos-Casals M, Bosch X, Stone JH (2014) The clinical spectrum of IgG4-related disease. Autoimmun Rev 13(12):1203–1210CrossRefPubMed

Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T et al (2012) Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Modern Rheumatol 22(1):21–30CrossRef

Uchida K, Masamune A, Shimosegawa T, Okazaki K (2012) Prevalence of IgG4-related disease in Japan based on nationwide survey in 2009. Int J Rheumatol 2012:1–5CrossRef

Wallace ZS, Miles G, Smolkina E, Petruski-Ivleva N, Madziva D, Cook C et al (2023) Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults. Ann Rheum Dis 82(7):957–962CrossRefPubMed

Gupta N, Mathew J, Mohan H, Chowdhury SD, Kurien RT, Christopher DJ et al (2018) Addition of second-line steroid sparing immunosuppressants like mycophenolate mofetil improves outcome of Immunoglobulin G4-related disease (IgG4-RD): a series from a tertiary care teaching hospital in South India. Rheumatol Int 38(2):203–209CrossRefPubMed

Kamisawa T, Okazaki K (2016) Diagnosis and treatment of IgG4-related disease. In: Okazaki K (ed) IgG4-Related Disease [Internet]. Cham: Springer International Publishing [cited 2023 Jul 13]. p. 19–33. (Current Topics in Microbiology and Immunology; vol. 401). Available from: http://link.springer.com/10.1007/82_2016_36

Gabbiani G (2021) 50 Years of myofibroblasts: how the myofibroblast concept evolved. In: Hinz B, Lagares D (eds) Myofibroblasts [Internet]. Springer US, New York, NY [cited 2023 Jul 13]. p. 1–5. (Methods in Molecular Biology; vol. 2299). Available from: https://link.springer.com/10.1007/978-1-0716-1382-5_1

Prabhu SM, Yadav V, Irodi A, Mani S, Varghese AM (2014) IgG4-related disease with sinonasal involvement: a case series. Indian J Radiol Imaging 24(2):117–120CrossRefPubMedPubMedCentral

Rohan A, Ravishankar B, Vishwanath S, Vankalakunti M, Kishore B, Ballal H (2014) IgG4 related renal disease: a wolf in sheep’s clothing. Indian J Nephrol 24(6):382CrossRefPubMedPubMedCentral

10.

Perugino CA, Mattoo H, Mahajan VS, Maehara T, Wallace ZS, Pillai S et al (2017) Emerging treatment models in rheumatology: IgG4-related disease: insights into human immunology and targeted therapies: etiology and treatment of IgG4-RD. Arthritis Rheumatol 69(9):1722–1732CrossRefPubMedPubMedCentral

11.

Mattoo H, Mahajan VS, Maehara T, Deshpande V, Della-Torre E, Wallace ZS et al (2016) Clonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol 138(3):825–838CrossRefPubMedPubMedCentral

12.

Haldar D, Hirschfield GM (2018)Deciphering the biology of IgG4-related disease: specific antigens and disease? Gut 67(4):602–605

13.

Della-Torre E, Feeney E, Deshpande V, Mattoo H, Mahajan V, Kulikova M et al (2015) B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. Ann Rheum Dis 74(12):2236–2243CrossRefPubMed

14.

Della-Torre E, Rigamonti E, Perugino C, Baghai-Sain S, Sun N, Kaneko N et al (2020) B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease. J Allergy Clin Immunol 145(3):968–981.e14CrossRefPubMed

15.

Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA et al (2015) Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 74(6):1171–1177CrossRefPubMed

16.

Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN et al (2015) International consensus guidance statement on the management and treatment of IgG4-related disease: international consensus statement on IgG4-RD management. Arthritis Rheumatol 67(7):1688–1699CrossRefPubMed

17.

Sisto M, Lisi S (2023) Immune and non-immune inflammatory cells involved in autoimmune fibrosis: new discoveries. JCM 12(11):3801CrossRefPubMedPubMedCentral

18.

Nambiar S, Oliver TI (2023) IgG4-related disease. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL). StatPearls Publishing

19.

Xu WL, Ling YC, Wang ZK, Deng F (2016) Diagnostic performance of serum IgG4 level for IgG4-related disease: a meta-analysis. Sci Rep 6(1):32035ADSCrossRefPubMedPubMedCentral

20.

Kawa S, Skold M, Ramsden D, Parker A, Harding S (2017) Serum IgG4 concentration in IgG4-related disease. Clin Lab [Internet] [cited 2023 Jul 17];63(09/2017). Available from: http://www.clin-lab-publications.com/article/2536

21.

Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH (2015) The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 74(1):14–18CrossRefPubMed

22.

Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T et al (2012) Consensus statement on the pathology of IgG4-related disease. Modern Pathol 25(9):1181–1192CrossRef

23.

Ryu JH, Horie R, Sekiguchi H, Peikert T, Yi ES (2012) Spectrum of disorders associated with elevated serum IgG4 levels encountered in clinical practice. Int J Rheumatol 2012:1–6CrossRef

24.

Kamisawa T, Okamoto A, Funata N (2005) Clinicopathological features of autoimmune pancreatitis in relation to elevation of serum IgG4. Pancreas 31(1):28–31CrossRefPubMed

25.

Tabata T, Kamisawa T, Takuma K, Egawa N, Setoguchi K, Tsuruta K et al (2011) Serial changes of elevated serum IgG4 levels in IgG4-related systemic disease. Intern Med 50(2):69–75CrossRefPubMed

26.

Campochiaro C, Ramirez G, Bozzolo E, Lanzillotta M, Berti A, Baldissera E et al (2016) IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients. Scand J Rheumatol 45(2):135–145CrossRefPubMed

27.

Kasashima S, Kawashima A, Kasashima F, Endo M, Matsumoto Y, Kawakami K (2018) Inflammatory features, including symptoms, increased serum interleukin-6, and C-reactive protein, in IgG4-related vascular diseases. Heart Vessels 33(12):1471–1481CrossRefPubMed

28.

Carruthers MN, Stone JH, Deshpande V, Khosroshahi A (2012) Development of an IgG4-RD responder index. Int J Rheumatol 2012:1–7CrossRef

29.

Handa T, Matsui S, Yoshifuji H, Kodama Y, Yamamoto H, Minamoto S et al (2018) Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease. Modern Rheumatol 28(5):838–844CrossRef

30.

Mattoo H, Mahajan VS, Della-Torre E, Sekigami Y, Carruthers M, Wallace ZS et al (2014) De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol 134(3):679–687CrossRefPubMedPubMedCentral

31.

Wallace ZS, Mattoo H, Carruthers M, Mahajan VS, Della Torre E, Lee H et al (2015) Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis 74(1):190–195CrossRefPubMed

32.

Nada R, Ramachandran R, Kumar A, Rathi M, Rawat A, Joshi K et al (2016) IgG4-related tubulointerstitial nephritis: a prospective analysis. Int J Rheum Dis 19(7):721–729CrossRefPubMed

33.

Chougule A, Bal A, Das A, Singh G (2015) IgG4 related sclerosing mastitis: expanding the morphological spectrum of IgG4 related diseases. Pathology 47(1):27–33CrossRefPubMed

34.

Yoshikawa T, Watanabe T, Minaga K, Kamata K, Kudo M (2019) Cytokines produced by innate immune cells in IgG4-related disease. Modern Rheumatol 29(2):219–225CrossRef

35.

Lighaam LC, Aalberse RC, Rispens T (2012) IgG4-related fibrotic diseases from an immunological perspective: regulators out of control? Int J Rheumatol 2012:1–6CrossRef

36.

Zen Y, Fujii T, Harada K, Kawano M, Yamada K, Takahira M et al (2007) Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 45(6):1538–1546CrossRefPubMed

37.

Tanaka A, Moriyama M, Nakashima H, Miyake K, Hayashida JN, Maehara T et al (2012) Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease. Arthritis Rheumatism 64(1):254–263CrossRefPubMed

38.

Akiyama M, Suzuki K, Yamaoka K, Yasuoka H, Takeshita M, Kaneko Y et al (2015) Brief report: number of circulating follicular helper 2 T cells correlates with IgG4 and Interleukin-4 levels and plasmablast numbers in IgG4-related disease: Tfh2 cells in IgG4-related disease. Arthritis Rheumatol 67(9):2476–2481CrossRefPubMed

39.

Kamekura R, Takano K, Yamamoto M, Kawata K, Shigehara K, Jitsukawa S et al (2017) Cutting edge: a critical role of lesional T follicular helper cells in the pathogenesis of IgG4-related disease. J Immunol 199(8):2624–2629CrossRefPubMed

40.

Maehara T, Mattoo H, Ohta M, Mahajan VS, Moriyama M, Yamauchi M et al (2017) Lesional CD4 ⁺ IFN-γ ⁺ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis. Ann Rheum Dis 76(2):377–385CrossRefPubMed

41.

Watanabe T, Yamashita K, Kudo M (2016) IgG4-related disease and innate immunity. In: Okazaki K (ed) IgG4-related disease [Internet]. Cham: Springer International Publishing [cited 2023 Jul 18]. p. 115–28. (Current Topics in Microbiology and Immunology; vol. 401). Available from: http://link.springer.com/10.1007/82_2016_42

42.

Ishiguro N, Moriyama M, Furusho K, Furukawa S, Shibata T, Murakami Y et al (2020) Activated M2 macrophages contribute to the pathogenesis of IgG4-related disease via toll-like receptor 7/interleukin-33 signaling. Arthritis Rheumatol 72(1):166–178CrossRefPubMed

Titel: Myofibroblast and pro-fibrotic cytokines in fibrosis of IgG4-related disease (IgG4-RD) patients from South Asia: preliminary data
verfasst von: Josna Joseph
V. Prabhu
Meera Thomas
Reka Karuppusami
Thomas Alex Kodiatte
Rajiv Michael
Manbha L. Rymbai
John Mathew
Publikationsdatum: 03.02.2024
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 3/2024
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-023-06861-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Myofibroblast and pro-fibrotic cytokines in fibrosis of IgG4-related disease (IgG4-RD) patients from South Asia: preliminary data